Overactive Bladder Clinical Trial
Official title:
Phase I Study for Evaluating the Safety and Applicability of a Novel Heat Flow Sensor Unit for Measuring Urinary Bladder Capacity
A novel sensor (a device named sensurine)was developed in the aim of real- time measurement of bladder volume. The sensurine device is a wearable, fully passive, non-invasive and compact heat flow sensor (patent pending) and electronic control unit. The device will serve as a tool for managing and treating bladder dysfunction (by behavioral treatment), such as overactive bladder without incontinence, urge incontinence and voiding difficulties. In this phase I of the clinical trial the sensor unit will be tested for technological feasibility demonstration and for collecting design data.
The Primary objectives are to asses the safety and the physical performance of the
SenseUrine’s sensor unit and to validate the concept of determining bladder volume by
measuring heat flow. The Secondary objective is to optimize the device accuracy Primary
endpoints: To show that the sensor has no negative effect on the subject, to determine
bladder urine volume, based on the sensor’s signals, in an accuracy of ±10% compared to the
actual volume. Secondary endpoint – to determine bladder urine volume, in an accuracy of
±10%, in different ambient conditions (temperature and clothing).
Inclusion criteria – All subjects will be aged 18-50, active, in good general health and
without urinary complaints or documented urinary tract dysfunctions. Exclusion criteria –
Pregnancy, breast feeding, known allergic sensitivity to medical adhesive tapes, cognitive
incompatibility and mental incompetence.
On the first visit, the subject will sign an informed consent form. A medical intake
including demographic data will be collected. Stage 1 will serve for basic testing of the
sensor unit and for measuring the maximal and minimal bladder volume. The sensor will be
attached to the lower abdomen wall and checked for functionality. Each subject will fill up
his bladder (by drinking water) until sensing a strong urge to void. The subject will then
void until he is empty into a measurement cup. Ultrasound measurement (US) of bladder
volume, and sensor signal will be read and recorded by a standard miliVoltmeter just before
and immediately after emptying the bladder. Sensor, US and cup measurement readings will not
be done by the same investigator. Continuing to stage 2 will depend on the preliminary
results (sensor readings compared to the measured volume and US readings) determining
feasibility.. Stage 2 will serve for measuring the dynamics of bladder heat conductivity
during the filling and voiding phases. On the 2nd visit the subject will fill up his bladder
by gradually drinking 500CC of water (over 60-90 minutes) until sensing a strong urge to
void. The subject will drink an additional 50-100CC of water and wait around 10 minutes in
the aim of achieving maximal bladder capacity. The sensor signals will be recorded from the
beginning of this bladder filling stage every 5-10 minutes. Then, the subject will be
requested to void in a controlled manner and to intentionally stop urinating after emptying
50-100CC of urine (voided volume will be determined by the measurement cup). The controlled
voiding of 50-100CC will be repeated until the bladder is empty. The sensor signals will be
read and recorded during both stages. Visit 3 will be performed in the same manner but in
different positions during measurements (supine-on the back, sides and front, sitting, and
standing). Visit 4 (final visit) will serve for demonstrating the sensor unit’s performance
in different ambient temperature and clothing. Two subjects will be randomly selected to
examine the sensor in an ambient of 15ºC (this will be controlled by an air-conditioned room
with an external thermometer) for measuring the dynamic range (maximal and minimal bladder
capacity). The same will be done at room temperature twice- with light and heavy clothing.
The other 2 subjects will be randomly selected to examine the sensor's performance in an
ambient of 40ºC (hot temperature will be achieved by an electric heater in a small room
controlled with an external thermometer) for measuring the dynamic range (maximal and
minimal bladder capacity). The same will be done at room temperature twice- with light and
heavy clothing.
All output signals will be logged and processed to show the correlation between the
calculated heat conductance of the bladder and the volume. A table consisting the calculated
indexes of conductivity vs. bladder volumes will be designed.
General: 10 subjects will be recruited by advertisement with notification of some
compensation for their time and travel to the study site. Every session will last about 4
hours long. In each working day 3-5 subjects will participate and the total trial period is
expected to be approximately 20 working days.
;
Allocation: Random Sample, Primary Purpose: Screening, Time Perspective: Longitudinal
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04578899 -
"The Effectiveness of Transvertebral Magnetic Neuromodulation in Patients With Detrusor Overactivity"
|
N/A | |
Active, not recruiting |
NCT03556891 -
Pivotal Study of eCoin for Overactive Bladder With Urgency Urinary Incontinence
|
N/A | |
Not yet recruiting |
NCT05977634 -
Transcutaneous Tibial Nerve Stimulation for Idiopathic Overactive Bladder
|
N/A | |
Completed |
NCT01955408 -
Severity of Overactive Bladder Symptoms in Patients After Synergo Treatment
|
N/A | |
Recruiting |
NCT06201013 -
Efficacy and Safety of Vitamin D in the Treatment of OAB-wet in Children
|
N/A | |
Recruiting |
NCT03727711 -
TPTNS: Home vs Hospital Treatment for Overactive Bladder
|
N/A | |
Completed |
NCT00768521 -
A Study to Test the Effects of Tolterodine Tartrate in Patients With Overactive Bladder (0000-107)
|
Phase 1 | |
Completed |
NCT03625843 -
Mindfulness Exercises to Reduce Anxiety and Pain During Urodynamic Testing
|
N/A | |
Completed |
NCT02211846 -
A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Mirabegron OCAS (Oral Controlled Absorption System) in Pediatric Subjects With Neurogenic Detrusor Overactivity or Overactive Bladder
|
Phase 1 | |
Completed |
NCT02857816 -
PRospective Study to Evaluate EffectivenesS With the NURO™ PErcutaneous Tibial Neuromodulation System in Patients With OAB
|
N/A | |
Completed |
NCT02835846 -
Investigation of the Effect of the Female Urinary Microbiome on Incontinence
|
Phase 4 | |
Withdrawn |
NCT02320201 -
Foot Neuromodulation for Overactive Bladder in Children
|
N/A | |
Completed |
NCT02202031 -
Controlling Urgency Through Relaxation Exercises
|
N/A | |
Completed |
NCT01437670 -
Observational Study to Estimate the Dry Mouth in OAB Patients With Solifenacin
|
N/A | |
Not yet recruiting |
NCT01423838 -
Comparison of Solifenacin and Oxybutynin in the Treatment of Overactive Bladder
|
Phase 4 | |
Completed |
NCT01458197 -
A Phase 2 Study to Compare the Efficacy and Tolerability of Tarafenacin 0.2 mg and Tarafenacin 0.4 mg to Placebo in Patients Suffering From Overactive Bladder.
|
Phase 2 | |
Not yet recruiting |
NCT01409512 -
Evaluation of Autonomic System Before and After Anticholinergic Treatment in Women With Overactive Bladder
|
N/A | |
Withdrawn |
NCT01210859 -
Effects of Antimuscarinic Drugs on Overactive Bladder (OAB) Symptoms After Insertion of Ureteral Stents
|
N/A | |
Terminated |
NCT01758848 -
Physical Therapy for Overactive Bladder
|
N/A | |
Terminated |
NCT01003249 -
Dysfunctional Voiding and Lower Urinary Tract Symptoms With Baclofen
|
Phase 4 |